In this study, we tested the hypothesis that obesity enhances LIFR signaling in TNBC, contributing to cancer progression, and tested the therapeutic potential of LIFR inhibition using the small-molecule inhibitor EC359. Here, LIFR is linked to obesity due to melanocortin 4 receptor deficiency.